Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Oct / New Biomarkers Identified for Early Mild Cognitive Impairment
Analytical science Biochemistry and molecular biology Molecular Pathology

New Biomarkers Identified for Early Mild Cognitive Impairment

Researchers use fNIRS and flow cytometry to uncover key neurovascular and biomolecular changes in mild cognitive impairment, offering potential for early diagnosis

By James Strachan 10/22/2024 News 1 min read

Share

Researchers have identified key biomarkers of mild cognitive impairment (MCI) – considered an early stage of cognitive decline and a precursor to conditions such as Alzheimer’s disease – involving neurovascular coupling (NVC), functional connectivity (FC), and cerebrovascular endothelial extracellular vesicles (CEEVs). The study highlights changes in these measurements as a potential diagnostic tool for detecting early stages of cognitive decline.

Credit: University of Oklahoma

Using a combination of functional near-infrared spectroscopy (fNIRS) and flow cytometry, the study examined how brain function and cerebrovascular health differ between individuals with MCI and healthy controls. The research centered on neurovascular coupling – how neuronal activity changes with cerebral blood flow. Researchers found that NVC responses in the left dorsolateral prefrontal cortex (LDLPFC), a critical brain region for working memory, were significantly impaired in participants with MCI compared with controls. These impairments were associated with decreased blood flow and diminished FC in the brain, suggesting that these markers could help differentiate between healthy aging and MCI.

Additionally, the researchers found higher concentrations of CEEVs in individuals with MCI – and that those levels correlated with small vessel ischemic damage in the brain, measured via MRI. The increased presence of these vesicles suggests that they could serve as biomarkers for cerebrovascular pathology and cognitive decline.

"Every brain is different, and there may be differing reasons for cognitive impairment, but having these predictors – measuring neurovascular coupling, functional connectivity, and CEEVs – potentially opens opportunities to develop individualized interventions, whether it's a pharmacological therapy or non-invasive brain stimulation, or something as simple as cognitive behavioral therapy," said Andriy Yabluchanskiy, OU College of Medicine associate professor of neurosurgery and co-author of the study, in a press release.

Researchers also used a machine-learning model to classify MCI using a combination of these factors – NVC, FC, and CEEV concentration. The model demonstrated an 85 percent accuracy rate, highlighting the potential of these biomarkers in early diagnosis.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Opening a Window into Brain Trauma
Analytical science
Opening a Window into Brain Trauma

January 18, 2024

4 min read

Raman spectroscopy shows promise as the first point-of-care diagnostic device for TBI

Could ≠ Should
Analytical science
Could ≠ Should

January 20, 2022

1 min read

The need to prevent the ordering of unnecessary tests

Diamonds Are a Diagnostician’s Best Friend
Analytical science
Diamonds Are a Diagnostician’s Best Friend

February 8, 2022

1 min read

A diagnostic sensor for rapid, cost-effective, and accurate detection of SARS-CoV-2

Hunting the Unknown
Analytical science
Hunting the Unknown

February 22, 2022

1 min read

When it comes to human health, we cannot ignore unknown molecules simply because they present analytical challenges

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.